Laboratory for cancer medicine

Selected publications

  1. Kalinowski FC, Brown RA, Ganda C, Giles KM, Epis MR, Horsham J, Leedman PJ. microRNA-7: a tumor suppressor miRNA with therapeutic potential. Int J Biochem Cell Biol 2014, S1357-2725. [NCBI PubMed Entry]
  2. Doan TB, Eriksson NA, Graham D, Funder JW, Simpson ER, Kuczek ES, Clyne C, Leedman PJ, Tilley WD, Fuller PJ, Muscat GEO, Clarke CL. Breast cancer prognosis predicted by nuclear receptor-coregulator networks. Molecular Oncology 2014, 8: 998-1013.
  3. Redfern AD, Colley SM, Beveridge D, Epis M, Li X, Foulds C, Stuart LM, O’Malley BW, Leedman PJ. RISC Proteins PACT, TRBP, and Dicer are SRA-binding nuclear receptor coregulators. Proc Nat Acad Sci USA 2013, 110; 6536-6541. [NCBI PubMed Entry]
  4. Giles KM, Kalinowski FC, Candy PA, Epis MR, Redfern AR, Zhang PM, Goodall GR, Leedman PJ. Axl mediates acquired resistance of head and neck cancer cells to epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther 2013, 12: 2541-2558. [NCBI PubMed Entry]
  5. Muscat G, Eriksson N, Byth K, Loi S, Graham D, Jindal S, Davis M, Clyne C, Funder JW, Simpson ER, Ragan M, Fuller PJ, Tilley W, Leedman PJ, Clarke C. Differential nuclear hormone receptor expression in human breast cancer: 8 nuclear receptors including the NR4A subgroup and EAR2 are highly expressed in breast cancer cohorts. Mol Endocrinology 2013, 27: 350-365.
  6. Singer S, Zhao R, Barsotti AM, Ouwehand A, Fazollahi M, Giles KM, Leedman PJ, Hess J, Grunwald D, Bussemaker HJ, Singer RH, Schirmacher P, Prives C. Nuclear pore component Nu98 is a potential tumor suppressor and regulates post-transcriptional expression of select p53 target genes. Molecular Cell 2012, 48: 1-12. [NCBI PubMed Entry]
  7. Kalinowski F, Giles KM, Candy PA, Ali A, Ganda C, Epis MR, Webster RJ, Leedman PJ. microRNA-7 regulates EGFR signaling and sensitivity of head and neck cancer cells to erlotinib. PLOSOne, 2012;7(10):e47067. [PLOSOne]
  8. Epis M, Giles KM, Candy PA, Barker A, Cohen RJ, Leedman PJ. Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells. J Biol Chem 2012, 287: 35251-35259.
  9. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. Regulation of EGFR signalling in human cancer cells by microRNA-7. J Biol Chem, 2009, 284: 5731-41. [NCBI PubMed Entry]
  10. Epis, M, Giles K, Barker A, Kendrick T, Leedman PJ. miR-331-3p regulates erbB-2 expression and androgen signaling in prostate cancer. J Biol Chem 2009, 284: 24696-24704. [NCBI PubMed Entry]
  11. Yu D, Tan AH-M, Hu X, Athanasopoulos V, Simpson N, Silva D, Hutloff A, Giles KM, Leedman PJ, Lam KP, Goodnow CC, Vinuesa CG. Roquin represses autoimmunity by limiting inducible T cell costimulator mRNA. Nature 2007, 450: 299-304.
  12. Hatchell EM, Colley S, Beveridge DJ, Epis MR, Stuart LM, Giles KM, Redfern AD, Miles LEC, Barker A, MacDonald L, Lanz RB, O’Malley BW, Leedman PJ. SLIRP, a novel SRA-binding protein, is a nuclear receptor co-repressor. Molecular Cell, 2006, 22: 657-668. [NCBI PubMed Entry]
Back To Top